|
CA2279675A1
(en)
|
1995-12-15 |
1997-06-16 |
Enzo Therapeutics, Inc. |
Property effecting and/or property exhibiting constructs for localizing a nucleic acid construct within a cell for therapeutic and diagnostic uses
|
|
FR2822164B1
(fr)
|
2001-03-19 |
2004-06-18 |
Centre Nat Rech Scient |
Polypeptides derives des arn polymerases, et leurs utilisations
|
|
EP4174179B1
(en)
|
2005-08-23 |
2025-05-07 |
The Trustees of the University of Pennsylvania |
Rna containing modified nucleosides and methods of use thereof
|
|
WO2007120863A2
(en)
|
2006-04-14 |
2007-10-25 |
Epicentre Technologies |
Kits and methods for generating 5' capped rna
|
|
WO2009021191A2
(en)
*
|
2007-08-08 |
2009-02-12 |
Barnes Wayne M |
Improved t7 expression system
|
|
WO2009135214A2
(en)
*
|
2008-05-02 |
2009-11-05 |
Epicentre Technologies Corporation |
Rna polyphosphatase compositions, kits, and uses thereof
|
|
KR20110044753A
(ko)
*
|
2008-08-08 |
2011-04-29 |
토소가부시키가이샤 |
기능 개선된 rna 중합효소 변이체
|
|
RU2592544C2
(ru)
*
|
2009-08-21 |
2016-07-20 |
Мериал, Инк. |
Способ получения рекомбинантного вирусного вектора apmv-8
|
|
JP2011223982A
(ja)
|
2010-03-30 |
2011-11-10 |
Tosoh Corp |
T7rnaポリメラーゼ融合蛋白質
|
|
EP2377938A1
(en)
|
2010-04-16 |
2011-10-19 |
Eukarys |
Capping-prone RNA polymerase enzymes and their applications
|
|
US9193959B2
(en)
*
|
2010-04-16 |
2015-11-24 |
Roche Diagnostics Operations, Inc. |
T7 RNA polymerase variants with enhanced thermostability
|
|
US8822663B2
(en)
|
2010-08-06 |
2014-09-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
RS63430B1
(sr)
|
2010-10-01 |
2022-08-31 |
Modernatx Inc |
Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
|
|
EP2691101A2
(en)
|
2011-03-31 |
2014-02-05 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
US8916352B2
(en)
|
2011-04-08 |
2014-12-23 |
Bio-Rad Laboratories, Inc. |
PCR reaction mixtures with decreased non-specific activity
|
|
CN103687957A
(zh)
|
2011-05-17 |
2014-03-26 |
现代治疗公司 |
工程化核酸及其用于非人类脊椎动物的方法
|
|
WO2012174271A2
(en)
*
|
2011-06-16 |
2012-12-20 |
The Regents Of The University Of California |
Synthetic gene clusters
|
|
WO2013039861A2
(en)
|
2011-09-12 |
2013-03-21 |
modeRNA Therapeutics |
Engineered nucleic acids and methods of use thereof
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
FR2981088B1
(fr)
*
|
2011-10-06 |
2013-11-29 |
Biomerieux Sa |
Arn polymerases mutees
|
|
WO2013130161A1
(en)
|
2011-12-14 |
2013-09-06 |
modeRNA Therapeutics |
Methods of responding to a biothreat
|
|
DE12858350T1
(de)
|
2011-12-16 |
2021-10-07 |
Modernatx, Inc. |
Modifizierte mrna zusammensetzungen
|
|
WO2013096709A2
(en)
|
2011-12-21 |
2013-06-27 |
modeRNA Therapeutics |
Methods of increasing the viability or longevity of an organ or organ explant
|
|
HUE047947T2
(hu)
|
2011-12-30 |
2020-05-28 |
Cellscript Llc |
In vitro szintetizált ssRNS elõállítása és alkalmazása emlõssejtekbe történõ bevezetésre biológiai vagy biokémiai hatás indukálására
|
|
US9045740B2
(en)
|
2012-02-24 |
2015-06-02 |
University Of Massachusetts |
Modified T7-related RNA polymerases and methods of use thereof
|
|
WO2013148867A1
(en)
*
|
2012-03-27 |
2013-10-03 |
Massachusetts Institute Of Technology |
Artificial sigma factors based on bisected t7 rna polymerase
|
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
HK1206601A1
(en)
|
2012-04-02 |
2016-01-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
|
EP2885419A4
(en)
|
2012-08-14 |
2016-05-25 |
Moderna Therapeutics Inc |
ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
|
|
EP2912180A1
(en)
*
|
2012-10-29 |
2015-09-02 |
Technische Universität Dortmund |
T7 rna polymerase variants and methods of using the same
|
|
HRP20220607T1
(hr)
|
2012-11-26 |
2022-06-24 |
Modernatx, Inc. |
Terminalno modificirana rna
|
|
EP2931319B1
(en)
|
2012-12-13 |
2019-08-21 |
ModernaTX, Inc. |
Modified nucleic acid molecules and uses thereof
|
|
WO2014093574A1
(en)
|
2012-12-13 |
2014-06-19 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for altering cell phenotype
|
|
US20160024181A1
(en)
|
2013-03-13 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
|
WO2014152211A1
(en)
|
2013-03-14 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US11377470B2
(en)
|
2013-03-15 |
2022-07-05 |
Modernatx, Inc. |
Ribonucleic acid purification
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
EP2983804A4
(en)
|
2013-03-15 |
2017-03-01 |
Moderna Therapeutics, Inc. |
Ion exchange purification of mrna
|
|
US20160032273A1
(en)
|
2013-03-15 |
2016-02-04 |
Moderna Therapeutics, Inc. |
Characterization of mrna molecules
|
|
EP2971033B8
(en)
*
|
2013-03-15 |
2019-07-10 |
ModernaTX, Inc. |
Manufacturing methods for production of rna transcripts
|
|
RS62529B1
(sr)
|
2013-07-11 |
2021-11-30 |
Modernatx Inc |
Kompozicije koje sadrže sintetičke polinukleotide koji kodiraju proteine povezane sa crispr i sintetičke sgrnk i postupci upotrebe
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
WO2015051169A2
(en)
|
2013-10-02 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
|
WO2015051214A1
(en)
|
2013-10-03 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
WO2015058069A1
(en)
|
2013-10-18 |
2015-04-23 |
Moderna Therapeutics, Inc. |
Compositions and methods for tolerizing cellular systems
|
|
DK3134131T3
(en)
|
2014-04-23 |
2022-02-07 |
Modernatx Inc |
Nucleic acid vaccines
|
|
US10286086B2
(en)
|
2014-06-19 |
2019-05-14 |
Modernatx, Inc. |
Alternative nucleic acid molecules and uses thereof
|
|
AU2015289583A1
(en)
|
2014-07-16 |
2017-02-02 |
Modernatx, Inc. |
Chimeric polynucleotides
|
|
EP3169783A4
(en)
|
2014-07-17 |
2018-10-03 |
Modernatx, Inc. |
Terminal modifications of polynucleotides
|
|
EP3247363A4
(en)
|
2015-01-21 |
2018-10-03 |
Moderna Therapeutics, Inc. |
Lipid nanoparticle compositions
|
|
WO2016164762A1
(en)
|
2015-04-08 |
2016-10-13 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
|
|
WO2016193226A1
(en)
|
2015-05-29 |
2016-12-08 |
Curevac Ag |
Method for adding cap structures to rna using immobilized enzymes
|
|
EP3307305A4
(en)
|
2015-06-10 |
2019-05-22 |
Modernatx, Inc. |
TARGETED ADAPTIVE VACCINES
|
|
WO2017011773A2
(en)
|
2015-07-15 |
2017-01-19 |
Modernatx, Inc. |
Codon-optimized nucleic acids encoding antibodies
|
|
WO2017015463A2
(en)
|
2015-07-21 |
2017-01-26 |
Modernatx, Inc. |
Infectious disease vaccines
|
|
WO2017015457A1
(en)
|
2015-07-21 |
2017-01-26 |
Modernatx, Inc. |
Ebola vaccine
|
|
WO2017019935A1
(en)
|
2015-07-30 |
2017-02-02 |
Modernatx, Inc. |
Multimeric mrna
|
|
US12150980B2
(en)
|
2015-07-30 |
2024-11-26 |
Modernatx, Inc. |
Concatemeric peptide epitope RNAs
|
|
US11564893B2
(en)
|
2015-08-17 |
2023-01-31 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
WO2017031241A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Rna mapping/fingerprinting
|
|
WO2017049245A2
(en)
|
2015-09-17 |
2017-03-23 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
PL4140491T3
(pl)
|
2015-09-21 |
2024-02-26 |
Trilink Biotechnologies, Llc |
Sposoby syntezy rna z kapem 5'
|
|
CA3001003A1
(en)
|
2015-10-05 |
2017-04-13 |
Modernatx, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
ES2862412T3
(es)
|
2015-10-14 |
2021-10-07 |
Translate Bio Inc |
Modificación de enzimas relacionados con el ARN para producción mejorada
|
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
|
WO2017066797A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Trinucleotide mrna cap analogs
|
|
MA45209A
(fr)
|
2015-10-22 |
2019-04-17 |
Modernatx Inc |
Vaccins contre les maladies sexuellement transmissibles
|
|
MA46080A
(fr)
|
2015-10-22 |
2019-07-10 |
Modernatx Inc |
Vaccins à base d'acide nucléique contre le virus varicelle-zona (vzv)
|
|
CA3002922A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
MA46023A
(fr)
|
2015-10-22 |
2019-07-03 |
Modernatx Inc |
Vaccin contre le virus de la grippe à large spectre
|
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
VACCINES AGAINST TROPICAL DISEASES
|
|
TW201729836A
(zh)
|
2015-10-22 |
2017-09-01 |
現代公司 |
呼吸道融合病毒疫苗
|
|
EP3718565B1
(en)
|
2015-10-22 |
2022-04-27 |
ModernaTX, Inc. |
Respiratory virus vaccines
|
|
MA46255A
(fr)
|
2015-10-22 |
2019-07-31 |
Modernatx Inc |
Vaccins anticancéreux
|
|
MA46024A
(fr)
|
2015-10-22 |
2019-07-03 |
Modernatx Inc |
Vaccin contre le virus de l'herpès simplex
|
|
JP7080172B2
(ja)
|
2015-12-10 |
2022-06-03 |
モデルナティエックス インコーポレイテッド |
治療薬の送達のための組成物及び方法
|
|
WO2017106799A1
(en)
|
2015-12-17 |
2017-06-22 |
Modernatx, Inc. |
POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE
|
|
US10465190B1
(en)
|
2015-12-23 |
2019-11-05 |
Modernatx, Inc. |
In vitro transcription methods and constructs
|
|
EP3882343A3
(en)
*
|
2016-01-13 |
2021-12-08 |
New England Biolabs, Inc. |
Thermostable variants of t7 rna polymerase
|
|
US20210206818A1
(en)
|
2016-01-22 |
2021-07-08 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
|
US12128113B2
(en)
|
2016-05-18 |
2024-10-29 |
Modernatx, Inc. |
Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
|
|
US20190382774A1
(en)
|
2016-05-18 |
2019-12-19 |
Modernatx, Inc. |
Polyribonucleotides containing reduced uracil content and uses thereof
|
|
WO2017201349A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding citrin for the treatment of citrullinemia type 2
|
|
MA45050A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant pour la lipoprotéine lipase destinés au traitement de l'hyperlipidémie
|
|
EP3458105B1
(en)
|
2016-05-18 |
2024-01-17 |
Modernatx, Inc. |
Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
|
|
WO2017201347A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
|
US20200085916A1
(en)
|
2016-05-18 |
2020-03-19 |
Modernatx, Inc. |
Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
|
|
CA3024509A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
|
WO2017201340A2
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding relaxin
|
|
US20190298657A1
(en)
|
2016-05-18 |
2019-10-03 |
Modernatx, Inc. |
Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
|
|
CA3024507A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding .alpha.-galactosidase a for the treatment of fabry disease
|
|
AU2017286606A1
(en)
|
2016-06-14 |
2018-12-13 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
CN106244608B
(zh)
*
|
2016-08-08 |
2019-10-25 |
中国科学技术大学 |
诱导的t7 rna聚合酶
|
|
ES2928475T3
(es)
|
2016-09-14 |
2022-11-18 |
Modernatx Inc |
Composiciones de ARN de alta pureza y métodos para su preparación
|
|
US10487105B2
(en)
|
2016-10-19 |
2019-11-26 |
Arcturus Therapeutics, Inc. |
Trinucleotide MRNA cap analogs
|
|
WO2018075980A1
(en)
|
2016-10-21 |
2018-04-26 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
SG11201903674YA
(en)
|
2016-10-26 |
2019-05-30 |
Modernatx Inc |
Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
|
|
WO2018081462A1
(en)
|
2016-10-26 |
2018-05-03 |
Modernatx, Inc. |
Methods and compositions for rna mapping
|
|
WO2018081788A1
(en)
|
2016-10-31 |
2018-05-03 |
Cornell University |
Methods of enhancing translation ability and stability of rna molecules, treatments, and kits
|
|
EP3538067A1
(en)
|
2016-11-08 |
2019-09-18 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
EP3538146A4
(en)
|
2016-11-11 |
2020-07-15 |
ModernaTX, Inc. |
INFLUENZA VACCINE
|
|
MA50335A
(fr)
|
2016-12-08 |
2020-08-19 |
Modernatx Inc |
Vaccins à acide nucléique contre des virus respiratoires
|
|
US11384352B2
(en)
|
2016-12-13 |
2022-07-12 |
Modernatx, Inc. |
RNA affinity purification
|
|
US20180243225A1
(en)
|
2017-01-25 |
2018-08-30 |
Modernatx, Inc. |
Ebola/marburg vaccines
|
|
MA47438A
(fr)
|
2017-02-01 |
2019-12-11 |
Modernatx Inc |
Structure secondaire de polynucléotide
|
|
EA201991804A1
(ru)
|
2017-02-01 |
2020-02-07 |
МОДЕРНАТиЭкс, ИНК. |
ИММУНОМОДУЛИРУЮЩИЕ ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ мРНК, КОДИРУЮЩЕЙ ПЕПТИДЫ С АКТИВИРУЮЩЕЙ ОНКОГЕННОЙ МУТАЦИЕЙ
|
|
JP7731656B2
(ja)
|
2017-02-01 |
2025-09-01 |
モデルナティエックス インコーポレイテッド |
Rna癌ワクチン
|
|
EP3582790A4
(en)
|
2017-02-16 |
2020-11-25 |
ModernaTX, Inc. |
VERY POWERFUL IMMUNOGENIC COMPOSITIONS
|
|
WO2018157009A1
(en)
|
2017-02-24 |
2018-08-30 |
Modernatx, Inc. |
Nucleic acid-based therapy of muscular dystrophies
|
|
EP3596041B1
(en)
|
2017-03-15 |
2022-11-02 |
ModernaTX, Inc. |
Compound and compositions for intracellular delivery of therapeutic agents
|
|
US11576961B2
(en)
|
2017-03-15 |
2023-02-14 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
WO2018170270A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Varicella zoster virus (vzv) vaccine
|
|
US11752206B2
(en)
|
2017-03-15 |
2023-09-12 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
WO2018170260A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
|
US20200030432A1
(en)
|
2017-03-17 |
2020-01-30 |
Modernatx, Inc. |
Zoonotic disease rna vaccines
|
|
US20200038499A1
(en)
|
2017-03-22 |
2020-02-06 |
Modernatx, Inc. |
Rna bacterial vaccines
|
|
US11905525B2
(en)
|
2017-04-05 |
2024-02-20 |
Modernatx, Inc. |
Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
|
|
US20200054737A1
(en)
|
2017-04-26 |
2020-02-20 |
Modema TX, Inc. |
Herpes simplex virus vaccine
|
|
EP3638215A4
(en)
|
2017-06-15 |
2021-03-24 |
Modernatx, Inc. |
RNA FORMULATIONS
|
|
WO2018232355A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna antibodies
|
|
US10034951B1
(en)
|
2017-06-21 |
2018-07-31 |
New England Biolabs, Inc. |
Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity
|
|
AU2018292104B2
(en)
*
|
2017-06-30 |
2025-03-27 |
Codexis, Inc. |
T7 RNA polymerase variants
|
|
US10793841B2
(en)
*
|
2017-06-30 |
2020-10-06 |
Codexis, Inc. |
T7 RNA polymerase variants
|
|
EP3668977A4
(en)
|
2017-08-18 |
2021-04-21 |
Modernatx, Inc. |
HPLC ANALYTICAL PROCESSES
|
|
US11912982B2
(en)
|
2017-08-18 |
2024-02-27 |
Modernatx, Inc. |
Methods for HPLC analysis
|
|
MA49913A
(fr)
|
2017-08-18 |
2021-05-05 |
Modernatx Inc |
Variants d'arn polymérase
|
|
EP3668522B1
(en)
|
2017-08-18 |
2024-09-11 |
ModernaTX, Inc. |
Efficacious mrna vaccines
|
|
JP7275111B2
(ja)
|
2017-08-31 |
2023-05-17 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子の生成方法
|
|
MA50253A
(fr)
|
2017-09-14 |
2020-07-22 |
Modernatx Inc |
Vaccins à arn contre le virus zika
|
|
US20190192646A1
(en)
|
2017-11-03 |
2019-06-27 |
Modernatx, Inc. |
Salmonella vaccines
|
|
US20200282047A1
(en)
|
2017-11-21 |
2020-09-10 |
Modernatx, Inc. |
Epstein-barr virus vaccines
|
|
EP3746090A4
(en)
|
2018-01-29 |
2021-11-17 |
ModernaTX, Inc. |
RSV RNA Vaccines
|
|
AU2019293244A1
(en)
|
2018-06-27 |
2021-02-11 |
Modernatx, Inc. |
Personalized cancer vaccine epitope selection
|
|
AU2019338557A1
(en)
|
2018-09-13 |
2021-03-25 |
Modernatx, Inc. |
Modified mRNA for the treatment of progressive familial intrahepatic cholestasis disorders
|
|
JP7526168B2
(ja)
|
2018-09-19 |
2024-07-31 |
モデルナティエックス インコーポレイテッド |
Peg脂質及びそれらの使用
|
|
EP3853202A1
(en)
|
2018-09-19 |
2021-07-28 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
US12383508B2
(en)
|
2018-09-19 |
2025-08-12 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
|
US20220125899A1
(en)
|
2018-11-07 |
2022-04-28 |
Modernatx, Inc. |
Rna cancer vaccines
|
|
CA3128215A1
(en)
|
2019-01-31 |
2020-08-06 |
Modernatx, Inc. |
Methods of preparing lipid nanoparticles
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
MA55037A
(fr)
|
2019-02-20 |
2021-12-29 |
Modernatx Inc |
Variants d'arn polymérase pour le coiffage co-transcriptionnel
|
|
CN113874502A
(zh)
*
|
2019-03-11 |
2021-12-31 |
摩登纳特斯有限公司 |
补料分批体外转录方法
|
|
MA55321A
(fr)
|
2019-03-15 |
2022-01-19 |
Modernatx Inc |
Vaccins à base d'arn contre le vih
|
|
AU2020283030A1
(en)
|
2019-05-31 |
2021-12-23 |
Modernatx, Inc. |
Expanded T cell assay
|
|
CA3149498A1
(en)
|
2019-08-14 |
2021-02-18 |
Modernatx, Inc. |
Processes for purifying downstream products of in vitro transcription
|
|
AU2020346041A1
(en)
|
2019-09-11 |
2022-03-31 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
US20220349006A1
(en)
|
2019-09-19 |
2022-11-03 |
Moderna TX, Inc. |
Cap guides and methods of use thereof for rna mapping
|
|
EP4088281A4
(en)
|
2020-01-10 |
2024-02-21 |
ModernaTX, Inc. |
VARIOUS AUTOCECODER FOR GENERATING BIOLOGICAL SEQUENCE
|
|
US20210228707A1
(en)
|
2020-01-28 |
2021-07-29 |
Modernatx, Inc. |
Coronavirus rna vaccines
|
|
IL295148A
(en)
|
2020-01-30 |
2022-09-01 |
Modernatx Inc |
Respiratory virus immunizing compositions
|
|
JP7438604B2
(ja)
|
2020-02-07 |
2024-02-27 |
モデルナティエックス インコーポレイテッド |
SARS-COV-2 mRNAドメインワクチン
|
|
WO2021211343A1
(en)
|
2020-04-13 |
2021-10-21 |
Modernatx, Inc. |
Zika virus mrna vaccines
|
|
WO2021222304A1
(en)
|
2020-04-27 |
2021-11-04 |
Modernatx, Inc. |
Sars-cov-2 rna vaccines
|
|
WO2021231963A1
(en)
|
2020-05-15 |
2021-11-18 |
Modernatx, Inc. |
Rna formulations for high volume distribution, and methods of using the same for treating covid-19
|
|
WO2021159130A2
(en)
|
2020-05-15 |
2021-08-12 |
Modernatx, Inc. |
Coronavirus rna vaccines and methods of use
|
|
EP4153238A4
(en)
|
2020-05-21 |
2024-12-18 |
ModernaTX, Inc. |
METHYLENE BLUE STABILIZED MRNA COMPOSITIONS
|
|
EP4162055A4
(en)
|
2020-06-05 |
2024-07-03 |
ModernaTX, Inc. |
Bacterial strains for dna production
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
US20230355743A1
(en)
|
2020-09-25 |
2023-11-09 |
Modernatx, Inc. |
Multi-proline-substituted coronavirus spike protein vaccines
|
|
US12329811B2
(en)
|
2021-01-11 |
2025-06-17 |
Modernatx, Inc. |
Seasonal RNA influenza virus vaccines
|
|
US20240139309A1
(en)
|
2021-01-15 |
2024-05-02 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines
|
|
JP2024503698A
(ja)
|
2021-01-15 |
2024-01-26 |
モデルナティエックス インコーポレイテッド |
変異型株ベースのコロナウイルスワクチン
|
|
EP4301405A4
(en)
|
2021-03-05 |
2025-01-29 |
ModernaTX, Inc. |
ENTEROVIRAL VACCINES WITH VIRUS-LIKE PARTICLES (VLP)
|
|
EP4313072A1
(en)
|
2021-03-26 |
2024-02-07 |
ModernaTX, Inc. |
Pertussis vaccine
|
|
EP4314000A1
(en)
|
2021-03-31 |
2024-02-07 |
ModernaTX, Inc. |
Synthesis of trinucleotide and tetranucleotide caps for mrna production
|
|
US20240209068A1
(en)
|
2021-04-01 |
2024-06-27 |
Modernatx, Inc. |
Mucosal expression of antibody structures and isotypes by mrna
|
|
JP2024512780A
(ja)
|
2021-04-01 |
2024-03-19 |
モデルナティエックス インコーポレイテッド |
多価rna組成物中のrna種の識別及び比率決定のための方法
|
|
WO2022221336A1
(en)
|
2021-04-13 |
2022-10-20 |
Modernatx, Inc. |
Respiratory syncytial virus mrna vaccines
|
|
EP4322997A4
(en)
|
2021-04-13 |
2025-02-26 |
ModernaTX, Inc. |
EPSTEIN-BARR VIRUS mRNA VACCINES
|
|
JP2024514182A
(ja)
|
2021-04-13 |
2024-03-28 |
モデルナティエックス インコーポレイテッド |
呼吸器ウイルス組み合わせワクチン
|
|
EP4322994A1
(en)
|
2021-04-14 |
2024-02-21 |
ModernaTX, Inc. |
Influenza-coronavirus combination vaccines
|
|
US20240226028A1
(en)
|
2021-04-29 |
2024-07-11 |
Modernatx, Inc. |
Lyophilization methods for preparing lipid formulated therapeutics
|